Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus

Cancer Journal

Volumn 17, Issue 5, 2011, Pages 300-301

  Melief, Cornelis J M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISA Pharmaceuticals   (Netherlands)

Author keywords

cancer vaccine; CD4 T cell CD8 T cell; Human papilloma virus type 16 (HPV16); Montanide ISA 51; peptide vaccine; synthetic vaccine; T lymphocyte; vulvar intraepithelial neoplasia (VIN)

Indexed keywords

CANCER VACCINE; FREUND ADJUVANT; PROTEIN E6; PROTEIN E7; SYNTHETIC PEPTIDE;

FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PRIORITY JOURNAL; REVIEW; VAGINAL INTRAEPITHELIAL NEOPLASIA;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRESSOR PROTEINS; T-LYMPHOCYTES; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC;

EID: 80053354606     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318235e0fe     Document Type: Review

References (10)

1. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351-360. (Pubitemid 351589701)
2. van der Burg SH, Arens R, Melief CJ. Immunotherapy for persistent viral infections and associated disease. Trends Immunol. 2011;32: 97-103.
3. van der Burg SH, Melief CJ. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol. 2011;23: 252-257.
4. Zwaveling S, Ferreira Mota SC, Nout J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002:169:350-358. (Pubitemid 34686155)
5. Vambutas A, DeVoti J, Nouri M, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine. 2005;23:5271-5280. (Pubitemid 41443433)
6. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res. 2008;14:169-177. (Pubitemid 351377993)
7. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178-187. (Pubitemid 351377994)
8. Kenter GG, Welters MJP, Valentijn AR, et al. Vaccination against HPV- 16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838-1847.
9. Welters MJP, Kenter GG, de Vos van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A. 2010;107:11895-11899.
10. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29:372-383.